• Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor investor investor investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor investor investor investor investor investor investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
*

N/A

Early VC
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
EUR20222023
Revenues00000000
% growth-9 %
EBITDA00000000
Profit00000000
% profit margin(441 %)(592 %)
EV00000000
EV / revenue00.0x00.0x
EV / EBITDA00.0x00.0x
R&D budget00000000

Source: Company filings or news article

Notes (0)
More about Idoven
Made with AI
Edit

Idoven is a health technology company focused on preventing cardiovascular disease through early detection and precision medicine. The company was founded in Madrid in 2018 by cardiologist Dr. Manuel Marina Breysse, serial entrepreneur Iñigo Juantegui, and machine learning scientist José María Lillo Castellano. The founding was the culmination of nearly a decade of research in cardiology and machine learning at Spain's National Center for Cardiovascular Research (CNIC). Dr. Marina's background as a sports cardiologist for elite Spanish athletes and his research in cardiac arrhythmias, combined with Lillo Castellano's expertise in machine learning and data analytics, formed the company's scientific foundation. Juantegui brought extensive entrepreneurial experience, having previously co-founded and sold the successful food delivery startup La Nevera Roja.

Idoven's core offering is Willem™, a cloud-based, AI-powered software platform that analyzes electrocardiograms (ECGs) to detect cardiac diseases. Certified as an EU MDR Medical Device Class IIa, the platform is designed to provide rapid and accurate ECG interpretation, augmenting the capabilities of clinicians. It can identify over 80 cardiac patterns, which constitute 90% of the most common heart issues, with cardiologist-level accuracy. A key feature of the Willem™ platform is its device-agnostic nature, allowing it to integrate with any ECG hardware—from 12-lead hospital machines to consumer wearables—and existing electronic health record (EHR) systems via APIs. This approach has enabled Idoven to build one of the world's largest and most diverse ECG databases for training its deep learning models.

The company operates on a B2B Software-as-a-Service (SaaS) model, partnering with medical device manufacturers, pharmaceutical companies, and clinical stakeholders. These partnerships focus on integrating Idoven's AI for faster diagnostics, patient risk stratification, and monitoring cardiac safety in drug trials. Idoven has secured significant funding from investors including Insight Partners, Northzone, and Wayra (Telefónica), as well as grants from the European Innovation Council (EIC). Notable angel investors include former Real Madrid goalkeeper Iker Casillas, who became an ambassador for the company after his own heart attack in 2019.

Keywords: AI cardiology, ECG analysis, cardiovascular disease detection, precision medicine, medical device software, arrhythmia detection, predictive analytics, health technology, digital health, cardiology-as-a-service, clinical decision support, remote patient monitoring, deep learning, machine learning, medical diagnostics, heart disease prevention, risk stratification, drug cardiac safety, Willem AI, electrocardiogram interpretation

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo